Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02928497 · ClinicalTrials.gov registry record · NA
Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 481
- Enrollment target
NCT02928497 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 481 participants.
The verdict
NCT02928497, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 481 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, including the post-implant medication regimen, for subjects with non-valvular atrial fibrillation who are deemed not to be eligible for anti-coagulation therapy to reduce the risk of stroke.
Interventions
- DEVICE WATCHMAN LAAC Device Implant
- DRUG Single Antiplatelet Therapy or No Therapy (Control)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 481 participants |
| Start Date | 2017-02-06 |
| Est. Completion | 2025-09-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02928497
The ClinicalTrials.gov registry entry for NCT02928497 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 481 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which WATCHMAN LAAC Device Implant is the first listed.
NCT02928497 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02928497 about?
NCT02928497 is a clinical study titled "Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation". The purpose of this study is to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, including the post-implant medication regimen, for subjects with non-valvular atrial fibrillation who are deemed not to be eligible for anti-coagulation therapy to red...
What is the current status of trial NCT02928497?
This trial is currently completed. It is a NA study. The enrollment target is 481 participants. The study started on 2017-02-06. Estimated completion is 2025-09-23.
What interventions are being tested in trial NCT02928497?
The interventions under investigation include: WATCHMAN LAAC Device Implant (DEVICE), Single Antiplatelet Therapy or No Therapy (Control) (DRUG).
Who is sponsoring clinical trial NCT02928497?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.